Laquinimod for treating relapsing-remitting multiple sclerosis
Following on from information provided to NICE by the company in May 2012, the appraisal of Laquinimod for treating relapsing-remitting multiple sclerosis [560] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 560
Topic area
  • Central nervous system

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Lyndsey Unwin
Project manager:

Jeremy Powell

Technical Lead: Helen Tucker

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 October 2022 Following on from information provided to NICE by the company in May 2012, the appraisal of Laquinimod for treating relapsing-remitting multiple sclerosis [560] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
31 October 2022 Discontinued. Following on from information provided to NICE by the company in May 2012, the appraisal of Laquinimod for treating relapsing-remitting multiple sclerosis [560] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
22 July 2014 We are suspending this appraisal. This is because the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has decided not to approve laquinimod for the treatment of relapsing-remitting multiple sclerosis.
20 May 2014 Following the opinion recently issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) we are rescheduling this appraisal. NICE cannot issue consultation documents or guidance on a technology until UK regulatory approval has been granted. We will therefore need to reschedule the appraisal to align with the latest regulatory expectations.
03 January 2014 A further draft scope consultation took place in October 2013

For further information on our processes and methods, please see our CHTE processes and methods manual